Microbot Medical (NASDAQ:MBOT) Stock Rating Upgraded by Wall Street Zen

Microbot Medical (NASDAQ:MBOT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Microbot Medical in a research note on Thursday, April 10th.

Microbot Medical Stock Down 5.6%

MBOT stock opened at $2.34 on Friday. The firm has a market capitalization of $85.12 million, a PE ratio of -2.92 and a beta of 1.14. Microbot Medical has a twelve month low of $0.82 and a twelve month high of $3.38. The stock’s 50 day moving average is $2.46 and its 200-day moving average is $1.87.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.07. On average, equities research analysts anticipate that Microbot Medical will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MBOT. Geode Capital Management LLC raised its stake in shares of Microbot Medical by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 10,442 shares during the period. Virtu Financial LLC purchased a new stake in Microbot Medical during the first quarter worth about $42,000. Goldman Sachs Group Inc. bought a new stake in Microbot Medical in the first quarter worth about $57,000. Finally, Renaissance Technologies LLC bought a new stake in Microbot Medical in the fourth quarter worth about $118,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.